| Year |
Citation |
Score |
| 2024 |
Omotoso MO, Lanis MR, Schneck JP. Artificial Antigen-Presenting Cell Fabrication for Murine T Cell Expansion. Current Protocols. 4: e976. PMID 38400601 DOI: 10.1002/cpz1.976 |
0.565 |
|
| 2024 |
Livingston NK, Hickey JW, Sim H, Salathe SF, Choy J, Kong J, Silver AB, Stelzel JL, Omotoso MO, Li S, Chaisawangwong W, Roy S, Ariail EC, Lanis MR, Pradeep P, ... ... Schneck JP, et al. In Vivo Stimulation of Therapeutic Antigen-Specific T Cells in an Artificial Lymph Node Matrix. Advanced Materials (Deerfield Beach, Fla.). e2310043. PMID 38358310 DOI: 10.1002/adma.202310043 |
0.581 |
|
| 2023 |
Zhu Y, Ma J, Shen R, Lin J, Li S, Lu X, Stelzel JL, Kong J, Cheng L, Vuong I, Yao ZC, Wei C, Korinetz NM, Toh WH, Choy J, ... ... Schneck JP, et al. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity. Nature Biomedical Engineering. PMID 38082180 DOI: 10.1038/s41551-023-01131-0 |
0.405 |
|
| 2023 |
Ben-Akiva E, Hickey JW, Meyer RA, Isser A, Shannon SR, Livingston NK, Rhodes KR, Kosmides AK, Warren TR, Tzeng SY, Schneck JP, Green JJ. Shape Matters: Biodegradable Anisotropic Nanoparticle Artificial Antigen Presenting Cells for Cancer Immunotherapy. Acta Biomaterialia. PMID 36812956 DOI: 10.1016/j.actbio.2023.02.023 |
0.555 |
|
| 2022 |
Lu J, Chen G, Sorokina A, Nguyen T, Wallace T, Nguyen C, Dunn C, Wang S, Ellis S, Shi G, McKelvey J, Sharov A, Liu YT, Schneck J, Weng NP. Cytomegalovirus infection reduced CD70 expression, signaling and expansion of viral specific memory CD8 T cells in healthy human adults. Immunity & Ageing : I & A. 19: 54. PMID 36368988 DOI: 10.1186/s12979-022-00307-7 |
0.389 |
|
| 2022 |
Isser A, Silver AB, Pruitt HC, Mass M, Elias EH, Aihara G, Kang SS, Bachmann N, Chen YY, Leonard EK, Bieler JG, Chaisawangwong W, Choy J, Shannon SR, Gerecht S, ... ... Schneck JP, et al. Nanoparticle-based modulation of CD4 T cell effector and helper functions enhances adoptive immunotherapy. Nature Communications. 13: 6086. PMID 36241639 DOI: 10.1038/s41467-022-33597-y |
0.547 |
|
| 2022 |
Chaisawangwong W, Wang H, Kouo T, Salathe SF, Isser A, Bieler JG, Zhang ML, Livingston NK, Li S, Horowitz JJ, Samet RE, Zyskind I, Rosenberg AZ, Schneck JP. Cross-reactivity of SARS-CoV-2- and influenza A-specific T cells in individuals exposed to SARS-CoV-2. Jci Insight. 7. PMID 36134660 DOI: 10.1172/jci.insight.158308 |
0.46 |
|
| 2022 |
Sung BY, Lin YH, Kong Q, Shah PD, Glick Bieler J, Palmer S, Weinhold KJ, Chang HR, Huang H, Avery RK, Schneck J, Chiu YL. Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1. The Journal of Clinical Investigation. 132. PMID 35040433 DOI: 10.1172/JCI140508 |
0.695 |
|
| 2021 |
Est-Witte SE, Livingston NK, Omotoso MO, Green JJ, Schneck JP. Nanoparticles for generating antigen-specific T cells for immunotherapy. Seminars in Immunology. 56: 101541. PMID 34922816 DOI: 10.1016/j.smim.2021.101541 |
0.517 |
|
| 2021 |
Rhodes KR, Isser A, Hickey JW, Ben-Akiva E, Meyer RA, Kosmides AK, Livingston NK, Tzeng SY, Schneck JP, Green JJ. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma. Acs Applied Materials & Interfaces. PMID 33573372 DOI: 10.1021/acsami.0c19955 |
0.542 |
|
| 2020 |
Isser A, Livingston NK, Schneck JP. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomaterials. 268: 120584. PMID 33338931 DOI: 10.1016/j.biomaterials.2020.120584 |
0.513 |
|
| 2020 |
Hickey JW, Isser A, Salathe SF, Gee KM, Hsiao MH, Shaikh W, Uzoukwu NC, Bieler JG, Mao HQ, Schneck JP. Adaptive Nanoparticle Platforms for High Throughput Expansion and Detection of Antigen-Specific T cells. Nano Letters. PMID 32594746 DOI: 10.1021/Acs.Nanolett.0C01511 |
0.625 |
|
| 2020 |
Bessell CA, Isser A, Havel JJ, Lee S, Bell DR, Hickey JW, Chaisawangwong W, Glick Bieler J, Srivastava R, Kuo F, Purohit T, Zhou R, Chan TA, Schneck JP. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. Jci Insight. 5. PMID 32324171 DOI: 10.1172/Jci.Insight.135597 |
0.54 |
|
| 2020 |
Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Rapid Expansion of Highly Functional Antigen-Specific T cells from Melanoma Patients by Nanoscale Artificial Antigen Presenting Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32241816 DOI: 10.1158/1078-0432.Ccr-19-3487 |
0.645 |
|
| 2019 |
Sabatino JJ, Wilson MR, Calabresi PA, Hauser SL, Schneck JP, Zamvil SS. Anti-CD20 therapy depletes activated myelin-specific CD8 T cells in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. PMID 31748274 DOI: 10.1073/Pnas.1915309116 |
0.509 |
|
| 2019 |
Hickey JW, Dong Y, Chung JW, Salathe SF, Pruitt HC, Li X, Chang C, Fraser AK, Bessell CA, Ewald AJ, Gerecht S, Mao HQ, Schneck JP. Engineering an Artificial T-Cell Stimulating Matrix for Immunotherapy. Advanced Materials (Deerfield Beach, Fla.). e1807359. PMID 30968468 DOI: 10.1002/Adma.201807359 |
0.616 |
|
| 2019 |
Pruitt HC, Lewis D, Ciccaglione M, Connor S, Smith Q, Hickey JW, Schneck JP, Gerecht S. Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 30776427 DOI: 10.1016/J.Matbio.2019.02.003 |
0.481 |
|
| 2019 |
Isser A, Schneck JP. High-affinity T cell receptors for adoptive cell transfer. The Journal of Clinical Investigation. 129: 69-71. PMID 30530992 DOI: 10.1172/Jci125471 |
0.59 |
|
| 2018 |
Hickey JW, Schneck JP. Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles. Journal of Visualized Experiments : Jove. PMID 30507913 DOI: 10.3791/58640 |
0.629 |
|
| 2018 |
Hickey JW, Isser AY, Vicente FP, Warner SB, Mao HQ, Schneck JP. Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties. Biomaterials. 187: 105-116. PMID 30312851 DOI: 10.1016/J.Biomaterials.2018.09.029 |
0.472 |
|
| 2018 |
Hickey JW, Kosmides AK, Schneck JP. Engineering Platforms for T Cell Modulation. International Review of Cell and Molecular Biology. 341: 277-362. PMID 30262034 DOI: 10.1016/Bs.Ircmb.2018.06.003 |
0.55 |
|
| 2018 |
Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP. Correction: Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget. 9: 32401. PMID 30190796 DOI: 10.18632/Oncotarget.26018 |
0.566 |
|
| 2018 |
Schappert A, Schneck JP, Suarez L, Oelke M, Schütz C. Soluble MHC class I complexes for targeted immunotherapy. Life Sciences. PMID 30102903 DOI: 10.1016/J.Lfs.2018.08.023 |
0.468 |
|
| 2018 |
Kosmides AK, Necochea K, Hickey JW, Schneck JP. Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation. Nano Letters. PMID 29488768 DOI: 10.1021/Acs.Nanolett.7B05284 |
0.572 |
|
| 2017 |
Sidhom JW, Bessell CA, Havel JJ, Kosmides A, Chan TA, Schneck JP. ImmunoMap: A Bioinformatics Tool for T-Cell Repertoire Analysis. Cancer Immunology Research. PMID 29263161 DOI: 10.1158/2326-6066.Cir-17-0114 |
0.571 |
|
| 2017 |
Rudqvist NP, Pilones KA, Lhuillier C, Wennerberg E, Sidhom JW, Emerson RO, Robins HS, Schneck J, Formenti SC, Demaria S. Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells. Cancer Immunology Research. PMID 29180535 DOI: 10.1158/2326-6066.Cir-17-0134 |
0.589 |
|
| 2017 |
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL, Chowell D, ... ... Schneck JP, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. PMID 29033130 DOI: 10.1016/J.Cell.2017.09.028 |
0.413 |
|
| 2017 |
Hickey JW, Vicente FP, Howard GP, Mao HQ, Schneck JP. Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation. Nano Letters. PMID 28994285 DOI: 10.1021/Acs.Nanolett.7B03734 |
0.588 |
|
| 2017 |
Kosmides AK, Sidhom JW, Fraser A, Bessell CA, Schneck JP. Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. Acs Nano. PMID 28589725 DOI: 10.1021/Acsnano.6B08152 |
0.5 |
|
| 2017 |
Sidhom J, Bessell CA, Havel JJ, Chan TA, Schneck JP. Abstract 976: ImmunoMap: a novel bioinformatics tool for immune cell repertoire analysis Cancer Research. 77: 976-976. DOI: 10.1158/1538-7445.Am2017-976 |
0.463 |
|
| 2017 |
Chan TA, Riaz N, Havel JJ, Makarov V, Desrichard A, Sims JS, Hodi FS, Martín-Algarra S, Sharfman WH, Bhatia S, Hwu W, Gajewski TF, Slingluff CL, Kendall SM, Chang H, ... ... Schneck JP, et al. Abstract 2988: Immunogenomic analyses of tumor cells and microenvironment in patients with advanced melanoma before and after treatment with nivolumab Cancer Research. 77: 2988-2988. DOI: 10.1158/1538-7445.Am2017-2988 |
0.362 |
|
| 2016 |
Kosmides AK, Meyer RA, Hickey JW, Aje K, Cheung KN, Green JJ, Schneck JP. Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. Biomaterials. 118: 16-26. PMID 27940380 DOI: 10.1016/J.Biomaterials.2016.11.038 |
0.5 |
|
| 2016 |
Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP. Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget. PMID 27602488 DOI: 10.18632/Oncotarget.11785 |
0.595 |
|
| 2016 |
Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL, Oelke M, Schneck JP, Webb TJ. VEGF potentiates GD3-mediated immune suppression by human ovarian cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27076627 DOI: 10.1158/1078-0432.Ccr-15-2518 |
0.39 |
|
| 2016 |
Chiu YL, Lin CH, Sung BY, Chuang YF, Schneck JP, Kern F, Pawelec G, Wang GC. Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4 + and CD8 + T-cell responses in older adults positively correlates with response size. Scientific Reports. 6: 19227. PMID 26778409 DOI: 10.1038/Srep19227 |
0.696 |
|
| 2016 |
Varela JC, Schuetz C, Oelke M, Schneck J. Rapid Expansion of Tumor-Specific T Cells Using Nanoparticle-Based Artificial Antigen Presenting Cells (aAPCs) Biology of Blood and Marrow Transplantation. 22: S146-S147. DOI: 10.1016/J.Bbmt.2015.11.490 |
0.564 |
|
| 2015 |
Perica K, Bieler JG, Schütz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP. Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. Acs Nano. 9: 6861-71. PMID 26171764 DOI: 10.1021/Acsnano.5B02829 |
0.726 |
|
| 2015 |
Meyer RA, Sunshine JC, Perica K, Kosmides AK, Aje K, Schneck JP, Green JJ. Immunoengineering: biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation (small 13/2015). Small (Weinheim An Der Bergstrasse, Germany). 11: 1612. PMID 25833364 DOI: 10.1002/Smll.201570077 |
0.626 |
|
| 2015 |
Najarro K, Nguyen H, Chen G, Xu M, Alcorta S, Yao X, Zukley L, Metter EJ, Truong T, Lin Y, Li H, Oelke M, Xu X, Ling SM, Longo DL, ... Schneck J, et al. Telomere Length as an Indicator of the Robustness of B- and T-Cell Response to Influenza in Older Adults. The Journal of Infectious Diseases. PMID 25828247 DOI: 10.1093/Infdis/Jiv202 |
0.391 |
|
| 2015 |
Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Medical Journal. 6: e0004. PMID 25717386 DOI: 10.5041/Rmmj.10179 |
0.507 |
|
| 2015 |
Meyer RA, Sunshine JC, Perica K, Kosmides AK, Aje K, Schneck JP, Green JJ. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small (Weinheim An Der Bergstrasse, Germany). 11: 1519-25. PMID 25641795 DOI: 10.1002/Smll.201402369 |
0.617 |
|
| 2015 |
Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Pasemann S, Mackensen A, Oelke M, Schneck JP, Schütz C. CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2075-83. PMID 25593301 DOI: 10.1158/1078-0432.Ccr-14-2696 |
0.612 |
|
| 2015 |
Perica K, Kosmides AK, Schneck JP. Linking form to function: Biophysical aspects of artificial antigen presenting cell design. Biochimica Et Biophysica Acta. 1853: 781-90. PMID 25200637 DOI: 10.1016/J.Bbamcr.2014.09.001 |
0.579 |
|
| 2014 |
Schütz C, Zoso A, Peng S, Bennett JD, Schneck JP, Oelke M. MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth. Immunity, Inflammation and Disease. 2: 181-92. PMID 25505552 DOI: 10.1002/Iid3.35 |
0.652 |
|
| 2014 |
Schütz C, Fleck M, Schneck JP, Oelke M. Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells. Journal of Visualized Experiments : Jove. e51859. PMID 25145915 DOI: 10.3791/51859 |
0.634 |
|
| 2014 |
Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. Acs Nano. 8: 2252-60. PMID 24564881 DOI: 10.1021/Nn405520D |
0.557 |
|
| 2014 |
Chiu YL, Shan L, Huang H, Haupt C, Bessell C, Canaday DH, Zhang H, Ho YC, Powell JD, Oelke M, Margolick JB, Blankson JN, Griffin DE, Schneck JP. Sprouty-2 regulates HIV-specific T cell polyfunctionality. The Journal of Clinical Investigation. 124: 198-208. PMID 24292711 DOI: 10.1172/Jci70510 |
0.713 |
|
| 2014 |
Sunshine JC, Perica K, Schneck JP, Green JJ. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials. 35: 269-77. PMID 24099710 DOI: 10.1016/J.Biomaterials.2013.09.050 |
0.541 |
|
| 2014 |
Perica K, De León Medero A, Durai M, Chiu YL, Bieler JG, Sibener L, Niemöller M, Assenmacher M, Richter A, Edidin M, Oelke M, Schneck J. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine : Nanotechnology, Biology, and Medicine. 10: 119-29. PMID 23891987 DOI: 10.1016/J.Nano.2013.06.015 |
0.732 |
|
| 2014 |
Chiu Y, Sung B, Bessell C, Oelke M, Schneck J. Wnt pathway activation functionally reprograms human antigen-specific T cells Journal For Immunotherapy of Cancer. 2: P4. DOI: 10.1186/2051-1426-2-S3-P4 |
0.734 |
|
| 2014 |
Schütz C, Perica K, Varela J, Haupt C, Oelke M, Schneck J. Antigen-specific T cell redirectors (ATR) for antigen-specific redirection of T cells to tumors Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P36 |
0.632 |
|
| 2014 |
Perica K, Bieler J, Schuetz C, Varela J, Oelke M, Schneck J. Enrichment and expansion with nanoscale artificial antigen presenting cells for T cell adoptive immunotherapy Journal For Immunotherapy of Cancer. 2: 34. DOI: 10.1186/2051-1426-2-S3-P34 |
0.619 |
|
| 2014 |
Kosmides AK, Schneck J. Dual-targeting nanoparticles for reprogrammed T cell responses in the tumor microenvironment Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P108 |
0.542 |
|
| 2014 |
Schuetz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck J. Redirection of Antigen-Specific T Cells to Tumor Cells Using Nanoparticle-Based Antigen-Specific Redirectors (ATRs) Blood. 124: 2753-2753. DOI: 10.1182/Blood.V124.21.2753.2753 |
0.628 |
|
| 2014 |
Varela JC, Perica K, Schuetz C, Bieler J, Haupt C, Oelke M, Schneck J. Enrichment and Expansion of Mart-1, NY-ESO and WT1 Specifc CD8+ T Cells Using Nano-Particle Artificial Antigen Presenting Cells (Nano-aAPCs) Blood. 124: 2443-2443. DOI: 10.1182/Blood.V124.21.2443.2443 |
0.668 |
|
| 2014 |
Chiu YL, Shan L, Huang H, Haupt C, Bessell C, Canaday DH, Zhang H, Ho YC, Powell JD, Oelke M, Margolick JB, Blankson JN, Griffin DE, Schneck JP. Sprouty-2 regulates HIV-specific T cell polyfunctionality Journal of Clinical Investigation. 124: 198-208. DOI: 10.1172/JCI70510 |
0.597 |
|
| 2013 |
Li X, Tsuji M, Schneck J, Webb TJ. Generation of Human iNKT Cell Lines. Bio-Protocol. 3. PMID 27570795 |
0.523 |
|
| 2013 |
Li X, Tsuji M, Schneck J, Webb TJ. Generation of Mouse iNKT Cell Lines. Bio-Protocol. 3. PMID 27280122 |
0.426 |
|
| 2013 |
de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, Marques ET. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs. Plos Neglected Tropical Diseases. 7: e1938. PMID 23383350 DOI: 10.1371/Journal.Pntd.0001938 |
0.568 |
|
| 2013 |
Perica K, Bieler JG, Medero ADL, Chiu Y, Durai M, Niemöller M, Assenmacher M, Richter A, Oelke M, Schneck J. Abstract 4531: Nanoscale Artificial Antigen Presenting Cells for T Cell Immunotherapy. Cancer Research. 73: 4531-4531. DOI: 10.1158/1538-7445.Am2013-4531 |
0.627 |
|
| 2012 |
Perica K, Bieler JG, Edidin M, Schneck J. Modulation of MHC binding by lateral association of TCR and coreceptor. Biophysical Journal. 103: 1890-8. PMID 23199917 DOI: 10.1016/J.Bpj.2012.09.011 |
0.565 |
|
| 2012 |
Webb TJ, Li X, Giuntoli RL, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, Oelke M, Schneck JP. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Research. 72: 3744-52. PMID 22649190 DOI: 10.1158/0008-5472.Can-11-2695 |
0.489 |
|
| 2012 |
Oelke M, Schneck J. Immunotherapy with enhanced self immune cells. Discovery Medicine. 4: 203-7. PMID 20704987 |
0.338 |
|
| 2012 |
Giuntoli R, Tseng J, Rogers O, Diaz-Montes T, Ibeanu O, Schneck J, Oelke M. Natural killer T cell expression associated with improved survival in epithelial ovarian cancer patients. Gynecologic Oncology. 125: S144. DOI: 10.1016/J.Ygyno.2011.12.353 |
0.439 |
|
| 2011 |
Boyle S, Kolin DL, Bieler JG, Schneck JP, Wiseman PW, Edidin M. Quantum dot fluorescence characterizes the nanoscale organization of T cell receptors for antigen. Biophysical Journal. 101: L57-9. PMID 22261075 DOI: 10.1016/J.Bpj.2011.10.028 |
0.455 |
|
| 2011 |
Lee JB, Oelke M, Ramachandra L, Canaday DH, Schneck JP. Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immunity & Ageing : I & A. 8: 6. PMID 21846352 DOI: 10.1186/1742-4933-8-6 |
0.519 |
|
| 2011 |
Xiao Z, Mohamood AS, Uddin S, Gutfreund R, Nakata C, Marshall A, Kimura H, Caturegli P, Womer KL, Huang Y, Jie C, Chakravarti S, Schneck JP, Yagita H, Hamad AR. Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development. The American Journal of Pathology. 179: 725-32. PMID 21718680 DOI: 10.1016/J.Ajpath.2011.04.016 |
0.433 |
|
| 2011 |
Chiu YL, Schneck JP, Oelke M. HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL. Journal of Visualized Experiments : Jove. PMID 21505415 DOI: 10.3791/2801 |
0.657 |
|
| 2011 |
Li Y, Tao SC, Zhu H, Schneck JP. High-throughput lectin microarray-based analysis of live cell surface glycosylation. Current Protocols in Protein Science / Editorial Board, John E. Coligan ... [Et Al.]. Unit12.9. PMID 21400689 DOI: 10.1002/0471140864.Ps1209S63 |
0.39 |
|
| 2010 |
Yue C, Oelke M, Paulaitis ME, Schneck JP. Novel cellular microarray assay for profiling T-cell peptide antigen specificities Journal of Proteome Research. 9: 5629-5637. PMID 20836567 DOI: 10.1021/Pr100447B |
0.765 |
|
| 2010 |
Schütz C, Oelke M, Schneck JP, Mackensen A, Fleck M. Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'. Immunotherapy. 2: 539-50. PMID 20636007 DOI: 10.2217/Imt.10.26 |
0.617 |
|
| 2010 |
Ndhlovu ZM, Oelke M, Schneck JP, Griffin DE. Dynamic regulation of functionally distinct virus-specific T cells. Proceedings of the National Academy of Sciences of the United States of America. 107: 3669-74. PMID 20133680 DOI: 10.1073/Pnas.0915168107 |
0.635 |
|
| 2010 |
Oelke M, Schneck JP. Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion. Immunologic Research. 47: 248-56. PMID 20087680 DOI: 10.1007/S12026-009-8156-Z |
0.514 |
|
| 2010 |
Wiseman PW, Kolin DL, Boyle S, Bieler JG, Schneck JP, Edidin M. K-Space Image Correlation Spectroscopy of Quantum dot Labeled T Cell Receptors Characterizes their Nanoscale Clustering in Living Cells Biophysical Journal. 98: 760a-761a. DOI: 10.1016/J.Bpj.2009.12.4176 |
0.464 |
|
| 2009 |
Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Research. 69: 9376-84. PMID 19934317 DOI: 10.1158/0008-5472.Can-09-0400 |
0.485 |
|
| 2009 |
Mertens J, Fabri M, Zingarelli A, Kubacki T, Meemboor S, Groneck L, Seeger J, Bessler M, Hafke H, Odenthal M, Bieler JG, Kalka C, Schneck JP, Kashkar H, Kalka-Moll WM. Streptococcus pneumoniae serotype 1 capsular polysaccharide induces CD8CD28 regulatory T lymphocytes by TCR crosslinking. Plos Pathogens. 5: e1000596. PMID 19779562 DOI: 10.1371/Journal.Ppat.1000596 |
0.532 |
|
| 2009 |
Ndhlovu ZM, Angenendt M, Heckel D, Schneck JP, Griffin DE, Oelke M. Development of an artificial-antigen-presenting-cell-based assay for the detection of low-frequency virus-specific CD8(+) T cells in whole blood, with application for measles virus. Clinical and Vaccine Immunology : Cvi. 16: 1066-73. PMID 19494085 DOI: 10.1128/Cvi.00365-08 |
0.618 |
|
| 2009 |
Webb TJ, Bieler JG, Schneck JP, Oelke M. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. Journal of Immunological Methods. 346: 38-44. PMID 19446558 DOI: 10.1016/J.Jim.2009.05.003 |
0.583 |
|
| 2009 |
Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. Journal of Immunological Methods. 345: 49-59. PMID 19374905 DOI: 10.1016/J.Jim.2009.04.002 |
0.519 |
|
| 2009 |
Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunology, Immunotherapy : Cii. 58: 209-20. PMID 18563409 DOI: 10.1007/S00262-008-0542-1 |
0.557 |
|
| 2008 |
Webb TJ, Giuntoli RL, Rogers O, Schneck J, Oelke M. Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7652-8. PMID 19047090 DOI: 10.1158/1078-0432.Ccr-08-1468 |
0.58 |
|
| 2008 |
Mohamood AS, Bargatze D, Xiao Z, Jie C, Yagita H, Ruben D, Watson J, Chakravarti S, Schneck JP, Hamad AR. Fas-mediated apoptosis regulates the composition of peripheral alphabeta T cell repertoire by constitutively purging out double negative T cells. Plos One. 3: e3465. PMID 18941614 DOI: 10.1371/Journal.Pone.0003465 |
0.599 |
|
| 2008 |
Tao SC, Li Y, Zhou J, Qian J, Schnaar RL, Zhang Y, Goldstein IJ, Zhu H, Schneck JP. Lectin microarrays identify cell-specific and functionally significant cell surface glycan markers. Glycobiology. 18: 761-9. PMID 18625848 DOI: 10.1093/Glycob/Cwn063 |
0.449 |
|
| 2008 |
Shaikh SR, Mitchell D, Carroll E, Li M, Schneck J, Edidin M. Differential effects of a saturated and a monounsaturated fatty acid on MHC class I antigen presentation Scandinavian Journal of Immunology. 68: 30-42. PMID 18533931 DOI: 10.1111/J.1365-3083.2008.02113.X |
0.467 |
|
| 2008 |
Schütz C, Fleck M, Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M. Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood. 111: 3546-52. PMID 18096763 DOI: 10.1182/blood-2007-09-113522 |
0.598 |
|
| 2008 |
Kapp M, Fick K, Jackob S, Thiele R, Oelke M, Wajant H, Schneck JP, Opitz A, Einsele H, Grigoleit GU. Evaluation of Different Co-Stimulatory Signals in the Priming and Expansion of HLA-B*0702/CMV_pp65 Restricted CTLs after Stimulation with aAPC Blood. 112: 4902-4902. DOI: 10.1182/Blood.V112.11.4902.4902 |
0.531 |
|
| 2007 |
Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nature Medicine. 13: 828-35. PMID 17603493 DOI: 10.1038/Nm1609 |
0.715 |
|
| 2007 |
Mohamood AS, Guler ML, Xiao Z, Zheng D, Hess A, Wang Y, Yagita H, Schneck JP, Hamad AR. Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically. The American Journal of Pathology. 171: 97-106. PMID 17591957 DOI: 10.2353/Ajpath.2007.070148 |
0.403 |
|
| 2007 |
Fahmy TM, Schneck JP, Saltzman WM. A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells. Nanomedicine : Nanotechnology, Biology, and Medicine. 3: 75-85. PMID 17379171 DOI: 10.1016/J.Nano.2006.11.010 |
0.55 |
|
| 2007 |
Deviren G, Gupta K, Paulaitis ME, Schneck JP. Detection of antigen-specific T cells on p/MHC microarrays. Journal of Molecular Recognition : Jmr. 20: 32-8. PMID 17094178 DOI: 10.1002/Jmr.805 |
0.792 |
|
| 2007 |
Gabrilovich D, Nagaraj S, Gupta K, Schneck J. Evaluation of antigen binding by CD8+ T cells after in vivo treatment with myeloid derived suppressor cells Nature Protocols. DOI: 10.1038/Nprot.2007.240 |
0.594 |
|
| 2006 |
Mohamood AS, Trujillo CJ, Zheng D, Jie C, Murillo FM, Schneck JP, Hamad AR. Gld mutation of Fas ligand increases the frequency and up-regulates cell survival genes in CD25+CD4+ TR cells. International Immunology. 18: 1265-77. PMID 16769751 DOI: 10.1093/Intimm/Dxl057 |
0.565 |
|
| 2005 |
Boin F, Wigley FM, Schneck JP, Oelke M, Rosen A. Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis. Annals of the New York Academy of Sciences. 1062: 137-45. PMID 16461796 DOI: 10.1196/Annals.1358.016 |
0.56 |
|
| 2005 |
Karabekian Z, Lytton SD, Silver PB, Sergeev YV, Schneck JP, Caspi RR. Antigen/MHC class II/Ig dimers for study of uveitogenic T cells: IRBP p161-180 presented by both IA and IE molecules. Investigative Ophthalmology & Visual Science. 46: 3769-76. PMID 16186361 DOI: 10.1167/Iovs.05-0187 |
0.559 |
|
| 2005 |
Oelke M, Krueger C, Giuntoli RL, Schneck JP. Artificial antigen-presenting cells: artificial solutions for real diseases. Trends in Molecular Medicine. 11: 412-20. PMID 16103011 DOI: 10.1016/J.Molmed.2005.07.005 |
0.597 |
|
| 2005 |
Oelke M, Krueger C, Schneck JP. Technological advances in adoptive immunotherapy. Drugs of Today (Barcelona, Spain : 1998). 41: 13-21. PMID 15753966 DOI: 10.1358/Dot.2005.41.1.875775 |
0.611 |
|
| 2004 |
Sirianni N, Ha PK, Oelke M, Califano J, Gooding W, Westra W, Whiteside TL, Koch WM, Schneck JP, DeLeo A, Ferris RL. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6929-37. PMID 15501971 DOI: 10.1158/1078-0432.Ccr-04-0672 |
0.348 |
|
| 2004 |
Krueger C, Schneck JP, Oelke M. Quality and quantity: new strategies to improve immunotherapy of cancer. Trends in Molecular Medicine. 10: 205-8. PMID 15121045 DOI: 10.1016/J.Molmed.2004.03.004 |
0.588 |
|
| 2004 |
Oelke M, Schneck JP. HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement. Clinical Immunology (Orlando, Fla.). 110: 243-51. PMID 15047202 DOI: 10.1016/J.Clim.2003.11.014 |
0.573 |
|
| 2003 |
Hamad AR, Mohamood AS, Trujillo CJ, Huang CT, Yuan E, Schneck JP. B220+ double-negative T cells suppress polyclonal T cell activation by a Fas-independent mechanism that involves inhibition of IL-2 production. Journal of Immunology (Baltimore, Md. : 1950). 171: 2421-6. PMID 12928389 DOI: 10.4049/Jimmunol.171.5.2421 |
0.58 |
|
| 2003 |
Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nature Medicine. 9: 619-24. PMID 12704385 DOI: 10.1038/Nm869 |
0.566 |
|
| 2002 |
Greten TF, Korangy F, Neumann G, Wedemeyer H, Schlote K, Heller A, Scheffer S, Pardoll DM, Garbe AI, Schneck JP, Manns MP. Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. Journal of Immunological Methods. 271: 125-35. PMID 12445736 DOI: 10.1016/S0022-1759(02)00346-0 |
0.535 |
|
| 2002 |
Fahmy TM, Bieler JG, Schneck JP. Probing T cell membrane organization using dimeric MHC-Ig complexes. Journal of Immunological Methods. 268: 93-106. PMID 12213346 DOI: 10.1016/S0022-1759(02)00203-X |
0.6 |
|
| 2002 |
Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nature Immunology. 3: 627-34. PMID 12055626 DOI: 10.1038/Ni806 |
0.571 |
|
| 2002 |
Greten TF, Schneck JP. Development and use of multimeric major histocompatibility complex molecules. Clinical and Diagnostic Laboratory Immunology. 9: 216-20. PMID 11874855 DOI: 10.1128/Cdli.9.2.216-220.2002 |
0.663 |
|
| 2001 |
Hamad ARA, Schneck JP. Antigen-induced T cell death is regulated by CD4 expression International Reviews of Immunology. 20: 535-546. PMID 11890611 DOI: 10.3109/08830180109045577 |
0.536 |
|
| 2001 |
O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide Journal of Immunology. 167: 2555-2560. PMID 11509595 DOI: 10.4049/Jimmunol.167.5.2555 |
0.611 |
|
| 2001 |
Hamad ARA, Srikrishnan A, Mirmonsef P, Broeren CPM, June CH, Pardoll D, Schneck JP. Lack of coreceptor allows survival of chronically stimulated double-negative α/β T cells: Implications for autoimmunity Journal of Experimental Medicine. 193: 1113-1121. PMID 11369783 DOI: 10.1084/Jem.193.10.1113 |
0.587 |
|
| 2001 |
Fahmy TM, Bieler JG, Edidin M, Schneck JP. Increased TCR avidity after T cell activation: A mechanism for sensing low-density antigen Immunity. 14: 135-143. PMID 11239446 DOI: 10.1016/S1074-7613(01)00096-6 |
0.623 |
|
| 2001 |
La Rosa C, Krishnan R, Markel S, Schneck JP, Houghten R, Pinilla C, Diamond DJ. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries Blood. 97: 1776-1786. PMID 11238120 DOI: 10.1182/Blood.V97.6.1776 |
0.503 |
|
| 2000 |
Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. The Journal of Infectious Diseases. 183: 197-205. PMID 11120926 DOI: 10.1086/317932 |
0.536 |
|
| 2000 |
Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex Immunity. 13: 529-538. PMID 11070171 DOI: 10.1016/S1074-7613(00)00052-2 |
0.565 |
|
| 2000 |
Schneck JP. Monitoring antigen-specific T cells using MHC-Ig dimers Immunological Investigations. 29: 163-169. PMID 10854185 DOI: 10.1002/0471142735.Im1702S35 |
0.634 |
|
| 1999 |
Selin LK, Lin MY, Kraemer KA, Pardoll DM, Schneck JP, Varga SM, Santolucito PA, Pinto AK, Welsh RM. Attrition of T cell memory: Selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses Immunity. 11: 733-742. PMID 10626895 DOI: 10.1016/S1074-7613(00)80147-8 |
0.504 |
|
| 1999 |
Carruth LM, Greten TF, Murray CE, Castro MG, Crone SN, Pavlat W, Schneck JP, Siliciano RF. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. Aids Research and Human Retroviruses. 15: 1021-34. PMID 10445814 DOI: 10.1089/088922299310539 |
0.38 |
|
| 1999 |
Lebowitz MS, O'Herrin SM, Hamad AR, Fahmy T, Marguet D, Barnes NC, Pardoll D, Bieler JG, Schneck JP. Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. Cellular Immunology. 192: 175-84. PMID 10087186 DOI: 10.1006/Cimm.1999.1441 |
0.494 |
|
| 1999 |
Nagai M, Kubota R, Schneck JP, Jacobson S. Phenotypic analysis of HTLV-I Tax11-19-specific CD8+ cells Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 20: A48. DOI: 10.1097/00042560-199904010-00177 |
0.441 |
|
| 1998 |
Hamad AR, O'Herrin SM, Lebowitz MS, Srikrishnan A, Bieler J, Schneck J, Pardoll D. Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor. The Journal of Experimental Medicine. 188: 1633-40. PMID 9802975 DOI: 10.1084/Jem.188.9.1633 |
0.614 |
|
| 1998 |
Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP. Direct visualization of antigen-specific T cells: HTLV-1 TAX11-19- specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients Proceedings of the National Academy of Sciences of the United States of America. 95: 7568-7573. PMID 9636190 DOI: 10.1073/Pnas.95.13.7568 |
0.592 |
|
| 1997 |
Johansen TE, McCullough K, Catipovic B, Su XM, Amzel M, Schneck JP. Peptide binding to MHC class I is determined by individual pockets in the binding groove Scandinavian Journal of Immunology. 46: 137-146. PMID 9583994 DOI: 10.1046/J.1365-3083.1997.D01-102.X |
0.303 |
|
| 1997 |
O'Herrin SM, Lebowitz MS, Bieler JG, al-Ramadi BK, Utz U, Bothwell AL, Schneck JP. Analysis of the expression of peptide-major histocompatibility complexes using high affinity soluble divalent T cell receptors. The Journal of Experimental Medicine. 186: 1333-45. PMID 9334373 DOI: 10.1084/Jem.186.8.1333 |
0.461 |
|
| 1997 |
Vuica M, Desiderio S, Schneck JP. Differential effects of B cell receptor and B cell receptor-FcγRIIB1 engagement on docking of Csk to GTPase-activating protein (GAP)-associated p62 Journal of Experimental Medicine. 186: 259-267. PMID 9221755 DOI: 10.1084/Jem.186.2.259 |
0.382 |
|
| 1996 |
O'Herrin SM, Kulkarni S, Kenealy WR, Fechner JH, Sollinger H, Schneck JP, Burlingham WJ. Expression of human recombinant β2-microglobulin by Aspergillus nidulans and its activity Human Immunology. 51: 63-72. PMID 8960907 DOI: 10.1016/S0198-8859(96)00224-8 |
0.331 |
|
| 1996 |
Čatipović B, Schneck JP, Brummet ME, Marsh DG, Rafnar T. Csk is constitutively associated with a 60-kDa tyrosine-phosphorylated protein in human T cells Journal of Biological Chemistry. 271: 9698-9703. PMID 8621646 DOI: 10.1074/Jbc.271.16.9698 |
0.46 |
|
| 1996 |
O'Herrin SM, Schneck JP. Expression and analysis of soluble MHC- and tcrimmunoglbulin super dimers Faseb Journal. 10. DOI: 10.1016/0198-8859(96)85211-6 |
0.477 |
|
| 1994 |
Čatipović B, Talluri G, Oh J, Wei T, Su XM, Johansen TE, Edidin M, Schneck JP. Analysis of the structure of empty and peptide-loaded major histocompatibility complex molecules at the cell surface Journal of Experimental Medicine. 180: 1753-1761. PMID 7525837 DOI: 10.1084/Jem.180.5.1753 |
0.408 |
|
| 1993 |
Dal Porto J, Johansen TE, Čatipović B, Parfiit DJ, Tuveson D, Gether U, Kozlowski S, Fearon DT, Schneck JP. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations Proceedings of the National Academy of Sciences of the United States of America. 90: 6671-6675. PMID 8341685 DOI: 10.1073/Pnas.90.14.6671 |
0.535 |
|
| 1993 |
Takeshita T, Kozlowski S, England RD, Brower R, Schneck J, Takahashi H, DeLisi C, Margulies DH, Berzofsky JA. Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules. International Immunology. 5: 1129-38. PMID 8241055 DOI: 10.1093/Intimm/5.9.1129 |
0.519 |
|
| 1992 |
Blok R, Margulies DH, Pease L, Ribaudo RK, Schneck JP, Mccluskey J. CD8 expression alters the fine specificity of an alloreactive MHC class I-specific T hybridoma International Immunology. 4: 455-466. PMID 1591216 DOI: 10.1093/Intimm/4.4.455 |
0.511 |
|
| 1992 |
Čatipović B, Dal Porto J, Mage M, Johansen TE, Schneck JP. Major histocompatibility complex conformational epitopes are peptide specific Journal of Experimental Medicine. 176: 1611-1618. PMID 1281212 DOI: 10.1084/Jem.176.6.1611 |
0.406 |
|
| 1991 |
DeVito LD, Mason B, Schneck J, Margulies DH, Sollinger HW, Burlingham WJ. Immunochemical analysis of a recombinant, genetically engineered, secreted HLA-A2/Q10b fusion protein. Human Immunology. 32: 125-33. PMID 1744002 DOI: 10.1016/0198-8859(91)90109-M |
0.338 |
|
| 1989 |
Schneck JP, Munitz T, Coligan JE, Maloy WL, Margulies DH, Singer A. Inhibition of allorecognition by an H-2Kb-derived peptide is evidence for a T-cell binding region on a major histocompatibility complex molecule. Proceedings of the National Academy of Sciences of the United States of America. 86: 8516-8520. PMID 2813409 DOI: 10.1073/Pnas.86.21.8516 |
0.477 |
|
| 1989 |
Schneck JP, Maloy WL, Coligan JE, Margulies DH. Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: estimation of the affinity of a T cell receptor for MHC. Cell. 56: 47-55. PMID 2783386 DOI: 10.1016/0092-8674(89)90982-3 |
0.446 |
|
| Show low-probability matches. |
